Teclistamab Combination Shows Higher Response Rate in Multiple Myeloma
January 27th 2023Emma Searle, PhD, discusses results of the MajestTEC-2 trial combining teclistamab with daratumumab and lenalidomide for patients with multiple myeloma presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Watch
Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple Myeloma
January 25th 2023Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.
Watch